SeaStar Medical faces derivative lawsuit over alleged false FDA approval statements

SeaStar Medical Holding Corp

Filed Dec 13, 2024 in US District Court for Colorado by shareholder Jose Lazo.
Defendants include CEO Eric Schlorff, former CFO, and certain current/former directors.
Alleges false/misleading statements about FDA prospects for Selective Cytopheretic Device and deficient internal controls.
Claims violations of Exchange Act Sections 14(a), 10(b), 21D, plus breach of fiduciary duty and unjust enrichment.
Seeks damages, restitution, and injunctive relief; substantially similar to a prior class action disclosed July 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.